Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $6.43 billion. The enterprise value is $5.79 billion.
Important Dates
The next estimated earnings date is Friday, August 8, 2025, before market open.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.29 million shares outstanding. The number of shares has increased by 1.67% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 184.29M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | -8.76% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 51.84% |
| Float | 81.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.78 |
| Forward PS | 5.48 |
| PB Ratio | 6.31 |
| P/TBV Ratio | 6.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.36.
| Current Ratio | 5.20 |
| Quick Ratio | 5.00 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.22 |
Financial Efficiency
Return on equity (ROE) is -20.00% and return on invested capital (ROIC) is -10.33%.
| Return on Equity (ROE) | -20.00% |
| Return on Assets (ROA) | -8.77% |
| Return on Invested Capital (ROIC) | -10.33% |
| Return on Capital Employed (ROCE) | -17.23% |
| Revenue Per Employee | $279,150 |
| Profits Per Employee | -$83,614 |
| Employee Count | 2,609 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 25.08 |
Taxes
In the past 12 months, Legend Biotech has paid $20.67 million in taxes.
| Income Tax | 20.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.93% in the last 52 weeks. The beta is 0.13, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -15.93% |
| 50-Day Moving Average | 32.20 |
| 200-Day Moving Average | 38.15 |
| Relative Strength Index (RSI) | 56.69 |
| Average Volume (20 Days) | 2,143,775 |
Short Selling Information
| Short Interest | 12.84M |
| Short Previous Month | 7.58M |
| Short % of Shares Out | 13.37% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.22 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $728.30 million and -$218.15 million in losses. Loss per share was -$1.19.
| Revenue | 728.30M |
| Gross Profit | 62.61M |
| Operating Income | -237.93M |
| Pretax Income | -287.07M |
| Net Income | -218.15M |
| EBITDA | -228.34M |
| EBIT | -237.93M |
| Loss Per Share | -$1.19 |
Full Income StatementBalance Sheet
The company has $1.01 billion in cash and $362.81 million in debt, giving a net cash position of $642.57 million or $3.49 per share.
| Cash & Cash Equivalents | 1.01B |
| Total Debt | 362.81M |
| Net Cash | 642.57M |
| Net Cash Per Share | $3.49 |
| Equity (Book Value) | 1.02B |
| Book Value Per Share | 5.53 |
| Working Capital | 984.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$263.31 million and capital expenditures -$9.86 million, giving a free cash flow of -$273.17 million.
| Operating Cash Flow | -263.31M |
| Capital Expenditures | -9.86M |
| Free Cash Flow | -273.17M |
| FCF Per Share | -$1.48 |
Full Cash Flow StatementMargins
Gross margin is 8.60%, with operating and profit margins of -32.67% and -29.95%.
| Gross Margin | 8.60% |
| Operating Margin | -32.67% |
| Pretax Margin | -27.11% |
| Profit Margin | -29.95% |
| EBITDA Margin | -31.35% |
| EBIT Margin | -32.67% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -3.39% |
| FCF Yield | -4.25% |
Dividend DetailsAnalyst Forecast
The average price target for Legend Biotech is $77.09, which is 120.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $77.09 |
| Price Target Difference | 120.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 36.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 7.3 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.3 |
| Piotroski F-Score | 2 |